1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Eosinophils	_	_	NNS	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	subset	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	granulocytes	_	_	NNS	_	_	_	_	_
7	mostly	_	_	RB	_	_	_	_	_
8	known	_	_	VBN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	their	_	_	PRP$	_	_	_	_	_
11	capacity	_	_	NN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	stimulate	_	_	VB	_	_	_	_	_
14	allergic	_	_	JJ	_	_	_	_	_
15	reactions	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	fight	_	_	VB	_	_	_	_	_
19	parasites	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Under	_	_	IN	_	_	_	_	_
2	normal	_	_	JJ	_	_	_	_	_
3	conditions	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	these	_	_	DT	_	_	_	_	_
6	cells	_	_	NNS	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	relatively	_	_	RB	_	_	_	_	_
9	rare	_	_	JJ	_	_	_	_	_
10	representing	_	_	VBG	_	_	_	_	_
11	1	_	_	CD	_	_	_	_	_
12	–	_	_	TO	_	_	_	_	_
13	3	_	_	CD	_	_	_	_	_
14	%	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	total	_	_	JJ	_	_	_	_	_
17	white	_	_	JJ	_	_	_	_	_
18	blood	_	_	NN	_	_	_	_	_
19	cells	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	During	_	_	IN	_	_	_	_	_
2	certain	_	_	JJ	_	_	_	_	_
3	inflammatory	_	_	JJ	_	_	_	_	_
4	conditions	_	_	NNS	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	i.	_	_	FW	_	_	_	_	_
7	e.	_	_	FW	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	allergies	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	parasitic	_	_	JJ	_	_	_	_	_
12	infections	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	autoimmune	_	_	JJ	_	_	_	_	_
15	diseases	_	_	NNS	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	eosinophils	_	_	NNS	_	_	_	_	_
18	can	_	_	MD	_	_	_	_	_
19	rapidly	_	_	RB	_	_	_	_	_
20	increase	_	_	VB	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	due	_	_	JJ	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	both	_	_	CC	_	_	_	_	_
25	de	_	_	FW	_	_	_	_	_
26	novo	_	_	FW	_	_	_	_	_
27	generation	_	_	NN	_	_	_	_	_
28	from	_	_	IN	_	_	_	_	_
29	bone	_	_	NN	_	_	_	_	_
30	marrow	_	_	NN	_	_	_	_	_
31	precursors	_	_	NNS	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	proliferation	_	_	NN	_	_	_	_	_
34	of	_	_	IN	_	_	_	_	_
35	tissue-resident	_	_	JJ	_	_	_	_	_
36	cells	_	_	NNS	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	infiltrating	_	_	VBG	_	_	_	_	_
39	inflamed	_	_	JJ	_	_	_	_	_
40	tissues	_	_	NNS	_	_	_	_	_
41	,	_	_	,	_	_	_	_	_
42	including	_	_	VBG	_	_	_	_	_
43	tumors	_	_	NNS	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	Tumor-associated	_	_	JJ	_	_	_	_	_
2	tissue	_	_	NN	_	_	_	_	_
3	eosinophilia	_	_	NN	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	described	_	_	VBN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	various	_	_	JJ	_	_	_	_	_
9	solid	_	_	JJ	_	_	_	_	_
10	tumors	_	_	NNS	_	_	_	_	_
11	although	_	_	IN	_	_	_	_	_
12	its	_	_	PRP$	_	_	_	_	_
13	prognostic	_	_	JJ	_	_	_	_	_
14	value	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	clinical	_	_	JJ	_	_	_	_	_
17	oncology	_	_	NN	_	_	_	_	_
18	remains	_	_	VBZ	_	_	_	_	_
19	controversial	_	_	JJ	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	vivo	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	eosinophils	_	_	NNS	_	_	_	_	_
5	were	_	_	VBD	_	_	_	_	_
6	shown	_	_	VBN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	exert	_	_	VB	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	protective	_	_	JJ	_	_	_	_	_
11	role	_	_	NN	_	_	_	_	_
12	inhibiting	_	_	VBG	_	_	_	_	_
13	tumor	_	_	NN	_	_	_	_	_
14	growth	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	mouse	_	_	NN	_	_	_	_	_
17	models	_	_	NNS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	melanoma	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	colorectal	_	_	JJ	_	_	_	_	_
22	cancer	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	hepatocellular	_	_	JJ	_	_	_	_	_
25	carcinoma	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	inducible	_	_	JJ	_	_	_	_	_
29	fibrosarcoma	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	eosinophils	_	_	NNS	_	_	_	_	_
4	infiltration	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	lung	_	_	NN	_	_	_	_	_
8	can	_	_	MD	_	_	_	_	_
9	prevent	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	formation	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	experimental	_	_	JJ	_	_	_	_	_
14	pulmonary	_	_	JJ	_	_	_	_	_
15	metastasis	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Eosinophils	_	_	NNS	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	equipped	_	_	VBN	_	_	_	_	_
4	with	_	_	IN	_	_	_	_	_
5	granules	_	_	NNS	_	_	_	_	_
6	carrying	_	_	VBG	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	plethora	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	cytotoxic	_	_	JJ	_	_	_	_	_
11	mediators	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	such	_	_	JJ	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	cationic	_	_	JJ	_	_	_	_	_
17	proteins	_	_	NNS	_	_	_	_	_
18	major	_	_	JJ	_	_	_	_	_
19	basic	_	_	JJ	_	_	_	_	_
20	protein	_	_	NN	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	MBP	_	_	NN	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	eosinophil	_	_	NN	_	_	_	_	_
26	cationic	_	_	JJ	_	_	_	_	_
27	protein	_	_	NN	_	_	_	_	_
28	(	_	_	-LRB-	_	_	_	_	_
29	ECP	_	_	NN	_	_	_	_	_
30	)	_	_	-RRB-	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	eosinophil	_	_	NN	_	_	_	_	_
33	peroxidase	_	_	NN	_	_	_	_	_
34	(	_	_	-LRB-	_	_	_	_	_
35	EPX	_	_	NN	_	_	_	_	_
36	)	_	_	-RRB-	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	granzymes	_	_	NN	_	_	_	_	_
40	(	_	_	-LRB-	_	_	_	_	_
41	granzyme-A	_	_	NN	_	_	_	_	_
42	in	_	_	IN	_	_	_	_	_
43	human	_	_	JJ	_	_	_	_	_
44	cells	_	_	NNS	_	_	_	_	_
45	,	_	_	,	_	_	_	_	_
46	granzyme-B	_	_	NN	_	_	_	_	_
47	in	_	_	IN	_	_	_	_	_
48	murine	_	_	NN	_	_	_	_	_
49	cells	_	_	NNS	_	_	_	_	_
50	)	_	_	-RRB-	_	_	_	_	_
51	that	_	_	WDT	_	_	_	_	_
52	can	_	_	MD	_	_	_	_	_
53	destroy	_	_	VB	_	_	_	_	_
54	target	_	_	NN	_	_	_	_	_
55	cells	_	_	NNS	_	_	_	_	_
56	or	_	_	CC	_	_	_	_	_
57	tissues	_	_	NNS	_	_	_	_	_
58	.	_	_	.	_	_	_	_	_


1	Indeed	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	eosinophils	_	_	NNS	_	_	_	_	_
4	were	_	_	VBD	_	_	_	_	_
5	shown	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	directly	_	_	RB	_	_	_	_	_
8	kill	_	_	VB	_	_	_	_	_
9	human	_	_	JJ	_	_	_	_	_
10	colon	_	_	NN	_	_	_	_	_
11	carcinoma	_	_	NN	_	_	_	_	_
12	cells	_	_	NNS	_	_	_	_	_
13	via	_	_	IN	_	_	_	_	_
14	release	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	granzyme-A	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	mechanism	_	_	NN	_	_	_	_	_
20	dependent	_	_	VBN	_	_	_	_	_
21	on	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	integrin	_	_	NN	_	_	_	_	_
24	CD11a/CD18	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	on	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	cytokine	_	_	NN	_	_	_	_	_
29	IL-18	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	eosinophils	_	_	NNS	_	_	_	_	_
5	activated	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	cross-linking	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	receptor	_	_	NN	_	_	_	_	_
11	2B4/CD244	_	_	NNP	_	_	_	_	_
12	exhibited	_	_	VBN	_	_	_	_	_
13	tumoricidal	_	_	JJ	_	_	_	_	_
14	activities	_	_	NNS	_	_	_	_	_
15	against	_	_	IN	_	_	_	_	_
16	human	_	_	JJ	_	_	_	_	_
17	B	_	_	NN	_	_	_	_	_
18	lymphoma	_	_	NN	_	_	_	_	_
19	cells	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	appears	_	_	VBZ	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	process	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	adhesion	_	_	NN	_	_	_	_	_
8	through	_	_	IN	_	_	_	_	_
9	integrins	_	_	NNS	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	important	_	_	JJ	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	eosinophil	_	_	NN	_	_	_	_	_
14	activation	_	_	NN	_	_	_	_	_
15	during	_	_	IN	_	_	_	_	_
16	inflammation	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	unclear	_	_	JJ	_	_	_	_	_
6	whether	_	_	IN	_	_	_	_	_
7	cell	_	_	NN	_	_	_	_	_
8	adhesion	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	degranulation	_	_	NN	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	sequential	_	_	JJ	_	_	_	_	_
13	or	_	_	CC	_	_	_	_	_
14	independent	_	_	JJ	_	_	_	_	_
15	events	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	mechanisms	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	granule	_	_	NN	_	_	_	_	_
8	protein	_	_	NN	_	_	_	_	_
9	secretion	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	i.	_	_	FW	_	_	_	_	_
12	e.	_	_	FW	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	degranulation	_	_	NN	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	eosinophils	_	_	NNS	_	_	_	_	_
18	leading	_	_	VBG	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	tumor	_	_	NN	_	_	_	_	_
21	cytotoxicity	_	_	NN	_	_	_	_	_
22	remain	_	_	VBP	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	be	_	_	VB	_	_	_	_	_
25	defined	_	_	VBN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	IL-33	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	epithelial-derived	_	_	JJ	_	_	_	_	_
5	“	_	_	``	_	_	_	_	_
6	alarmin	_	_	NN	_	_	_	_	_
7	”	_	_	''	_	_	_	_	_
8	playing	_	_	VBG	_	_	_	_	_
9	multiple	_	_	JJ	_	_	_	_	_
10	functions	_	_	NNS	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	Th2-related	_	_	JJ	_	_	_	_	_
13	immunopathologies	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	recently	_	_	RB	_	_	_	_	_
16	implied	_	_	VBN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	cancer	_	_	NN	_	_	_	_	_
19	immunity	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	exerting	_	_	VBG	_	_	_	_	_
22	pro-	_	_	JJ	_	_	_	_	_
23	or	_	_	CC	_	_	_	_	_
24	anti-tumoral	_	_	JJ	_	_	_	_	_
25	activities	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	depending	_	_	VBG	_	_	_	_	_
28	on	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	tumor	_	_	NN	_	_	_	_	_
31	type	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	microenvironmental	_	_	JJ	_	_	_	_	_
34	factors	_	_	NNS	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Tumor	_	_	NN	_	_	_	_	_
2	over-expression	_	_	NN	_	_	_	_	_
3	or	_	_	CC	_	_	_	_	_
4	exogenous	_	_	JJ	_	_	_	_	_
5	administration	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	IL-33	_	_	NNP	_	_	_	_	_
8	promotes	_	_	VBZ	_	_	_	_	_
9	anti-tumor	_	_	JJ	_	_	_	_	_
10	immune	_	_	JJ	_	_	_	_	_
11	responses	_	_	NNS	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	vivo	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	models	_	_	NNS	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	melanoma	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	acute	_	_	JJ	_	_	_	_	_
20	myeloid	_	_	NN	_	_	_	_	_
21	leukemia	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	lung	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	colorectal	_	_	JJ	_	_	_	_	_
26	cancer	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	IL-33	_	_	NNP	_	_	_	_	_
2	drives	_	_	VBZ	_	_	_	_	_
3	substantial	_	_	JJ	_	_	_	_	_
4	recruitment	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	eosinophils	_	_	NNS	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	inflamed	_	_	VBN	_	_	_	_	_
9	sites	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	such	_	_	JJ	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	lung	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	likely	_	_	JJ	_	_	_	_	_
17	by	_	_	IN	_	_	_	_	_
18	promoting	_	_	VBG	_	_	_	_	_
19	eosinophilopoiesis	_	_	NN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	bone	_	_	NN	_	_	_	_	_
23	marrow	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	IL-33	_	_	NNP	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	induce	_	_	VB	_	_	_	_	_
7	eosinophil	_	_	NN	_	_	_	_	_
8	superoxide	_	_	NN	_	_	_	_	_
9	anion	_	_	NN	_	_	_	_	_
10	production	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	promote	_	_	VB	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	survival	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	eosinophils	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	initially	_	_	RB	_	_	_	_	_
3	reported	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	IL-33	_	_	NNP	_	_	_	_	_
6	inhibits	_	_	VBZ	_	_	_	_	_
7	tumor	_	_	NN	_	_	_	_	_
8	growth	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	pulmonary	_	_	JJ	_	_	_	_	_
11	metastasis	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	vivo	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	an	_	_	DT	_	_	_	_	_
16	eosinophil-dependent	_	_	JJ	_	_	_	_	_
17	manner	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Subsequent	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	confirmed	_	_	VBD	_	_	_	_	_
4	eosinophil-mediated	_	_	JJ	_	_	_	_	_
5	anti-tumoral	_	_	JJ	_	_	_	_	_
6	effects	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	IL-33	_	_	NN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	pre-clinical	_	_	JJ	_	_	_	_	_
11	models	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	metastatic	_	_	JJ	_	_	_	_	_
14	peritoneal	_	_	JJ	_	_	_	_	_
15	cancer	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	hepatocellular	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	prostatic	_	_	JJ	_	_	_	_	_
21	cancer	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	suggested	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	eosinophils	_	_	NNS	_	_	_	_	_
6	recruited	_	_	VBN	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	IL-33	_	_	NNP	_	_	_	_	_
9	might	_	_	MD	_	_	_	_	_
10	either	_	_	CC	_	_	_	_	_
11	function	_	_	VB	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	accessory	_	_	NN	_	_	_	_	_
14	cells	_	_	NNS	_	_	_	_	_
15	attracting	_	_	VBG	_	_	_	_	_
16	CD8	_	_	NN	_	_	_	_	_
17	T	_	_	NN	_	_	_	_	_
18	cells	_	_	NNS	_	_	_	_	_
19	or	_	_	CC	_	_	_	_	_
20	play	_	_	VB	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	direct	_	_	JJ	_	_	_	_	_
23	antitumor	_	_	JJ	_	_	_	_	_
24	role	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Here	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	further	_	_	RB	_	_	_	_	_
5	investigated	_	_	VBD	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	anti-tumoral	_	_	JJ	_	_	_	_	_
8	mechanisms	_	_	NNS	_	_	_	_	_
9	operated	_	_	VBN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	eosinophils	_	_	NNS	_	_	_	_	_
12	following	_	_	VBG	_	_	_	_	_
13	activation	_	_	NN	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	IL-33	_	_	NNP	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	By	_	_	IN	_	_	_	_	_
2	using	_	_	VBG	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	panel	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	tumor	_	_	NN	_	_	_	_	_
7	cell	_	_	NN	_	_	_	_	_
8	lines	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	we	_	_	PRP	_	_	_	_	_
11	show	_	_	VBP	_	_	_	_	_
12	that	_	_	IN	_	_	_	_	_
13	IL-33	_	_	NNP	_	_	_	_	_
14	promotes	_	_	VBZ	_	_	_	_	_
15	tumoricidal	_	_	JJ	_	_	_	_	_
16	functions	_	_	NNS	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	eosinophils	_	_	NNS	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	vitro	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	vivo	_	_	NN	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	cell	_	_	NN	_	_	_	_	_
27	adhesion-dependent	_	_	JJ	_	_	_	_	_
28	manner	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	through	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	integrin	_	_	NN	_	_	_	_	_
33	CD11b/CD18	_	_	NN	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	by	_	_	IN	_	_	_	_	_
36	inducing	_	_	VBG	_	_	_	_	_
37	lytic	_	_	JJ	_	_	_	_	_
38	granule	_	_	NN	_	_	_	_	_
39	convergence	_	_	NN	_	_	_	_	_
40	to	_	_	TO	_	_	_	_	_
41	the	_	_	DT	_	_	_	_	_
42	immune	_	_	JJ	_	_	_	_	_
43	synapse	_	_	NN	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	data	_	_	NNS	_	_	_	_	_
3	provide	_	_	VBP	_	_	_	_	_
4	mechanistic	_	_	JJ	_	_	_	_	_
5	insights	_	_	NNS	_	_	_	_	_
6	into	_	_	IN	_	_	_	_	_
7	eosinophil	_	_	NN	_	_	_	_	_
8	anti-tumor	_	_	JJ	_	_	_	_	_
9	activities	_	_	NNS	_	_	_	_	_
10	stimulated	_	_	VBN	_	_	_	_	_
11	by	_	_	IN	_	_	_	_	_
12	IL-33	_	_	NN	_	_	_	_	_
13	that	_	_	WDT	_	_	_	_	_
14	involve	_	_	VBP	_	_	_	_	_
15	cell	_	_	NN	_	_	_	_	_
16	contact	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	directional	_	_	JJ	_	_	_	_	_
19	secretion	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	granules	_	_	NNS	_	_	_	_	_
22	toward	_	_	IN	_	_	_	_	_
23	target	_	_	NN	_	_	_	_	_
24	tumor	_	_	NN	_	_	_	_	_
25	cells	_	_	NNS	_	_	_	_	_
26	enhancing	_	_	VBG	_	_	_	_	_
27	killing	_	_	VBG	_	_	_	_	_
28	efficiency	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_

